The sensor module and associated reference designs for consumer products integrate hardware and application firmware to enable wearable devices to monitor multiple biomarkers, including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. The full-stack, “clinic-on-the-wrist” digital health sensor system features a wristband that contains the sensor module and communicates with custom cloud-based analytical engines via a smartphone app. T

The wristband, says the company, will be used in a sequence of in-house human studies in the coming months.

“Our full-stack sensor solution, which brings together optical and electronic hardware, firmware, algorithms, and cloud-based analytics, is an exciting milestone on our roadmap,” says Dr. Andrew Rickman, chief executive officer and founder of Rockley Photonics. “Our reference designs will significantly aid our customers and partners with the deployment of our technology and accelerate their own scalable, high-volume product delivery. We believe that combining machine learning algorithms with continuous monitoring of an extended set of biomarkers from accessible wearable devices will provide new actionable insights to enhance and transform digital healthcare.”

Through its “clinic-on-the-wrist” technology utilizing a miniaturized chip solution that provides continuous, non-invasive monitoring of core biomarkers, the company says that it expects to be able to overcome the key challenges associated with mobile wellness monitoring. While many of today’s wearable consumer electronic devices use green light-emitting diodes (LEDs) to monitor heart rate, Rockley’s infrared (IR) spectrophotometers can detect and monitor a much wider range of biomarkers, which could dramatically increase the functionality of wearable devices.

The central and differentiating element of the sensing system is a non-invasive sensor module based on the company’s platform’s spectroscopy technology. Unlike more common spectroscopy solutions, which use broad-spectrum light sources, Rockley’s sensor module generates a large number of discrete laser outputs from a single silicon chip covering a broad optical band.

The sensor non-invasively probes beneath the skin to analyze blood, interstitial fluids, and various layers of the dermis for constituents and physical phenomena of interest. Such biomarkers have historically been measurable only by using bench-top equipment. In addition, says the company, its innovative architecture delivers several milliwatts of optical output power per wavelength channel, which is key to achieving the high signal-to-noise ratio required for signal analysis from a small wearable.

The company is initially targeting the consumer electronics market, in which significant advances in digital personal health and fitness monitoring have occurred in recent years. The company says that it is also actively pursuing the application of its technologies with leading medical device companies as biomarker monitoring can advance digital health applications and improve disease prevention, detection, and management.

In March, the company entered into a definitive agreement to combine with SC Health Corp. (NYSE: SCPE), a publicly traded special purpose acquisition company (SPAC). The transaction will result in Rockley becoming a publicly traded company on the NYSE under the symbol “RKLY.”

Rockley Photonics

Related articles:
‘Clinic-on-the-wrist’ photonics sensing company gets SPAC deal
Wearables to transform traditional healthcare model
Wearable health AI system aims to detect COVID-19 before symptoms
Medical wearables market forecast to reach $19.7B by 2024


Linked Articles